Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: PTMA

Summary for PTMA

Gene information	Gene symbol	PTMA
	Ensembl ID	ENSG00000187514
	Entrez ID	5757
	Gene name	prothymosin alpha
	Synonyms	TMSA
	Gene type	protein_coding
	UniProtAcc	NA

Top

Dataset with differentially expressed gene: PTMA

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	-0.774398	2.51e-13
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	0.92644	0.00e+00
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	0.844867	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.518247	3.21e-19
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Progenitors	0.604823	2.91e-07
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.470388	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.369441	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.261626	5.32e-28
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	-0.330645	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	-0.285869	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	1.18166	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	-0.43238	9.97e-29
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	0.313018	3.99e-31
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	0.482323	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	0.304224	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	0.291875	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	0.258731	6.81e-43
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.282001	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	0.478132	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Plasma cells	-0.578794	5.52e-08
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Plasma cells	-0.63724	1.34e-24
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	-0.309991	2.89e-09
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Erythrocytes	-1.73163	2.37e-41
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	NK cells	-0.752743	2.11e-03
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	-0.526822	3.41e-08
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-0.362755	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.466671	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.374038	4.92e-16
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	0.44916	8.95e-25
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	-0.264617	4.35e-11
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Erythrocytes	-0.524789	2.81e-31
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.748795	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	-0.356263	7.99e-13
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-0.397	0.00e+00
GSE161195	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone)	post	Malignant cells	0.738801	0.00e+00
GSE161195	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone)	pre	Malignant cells	0.304547	0.00e+00
GSE158457	PDX cells	Cell line	Acute lymphoblastic leukemia	T-cell acute lymphoblastic leukemia (ALL)	Targeted therapy	dasatinib	NA	Malignant cells	-0.549441	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	0.409249	0.00e+00
GSE149214	PC9 cell line	Cell line	Lung cancer	EGFR-mutated non-small cell lung cancer (NSCLC)	Targeted therapy	erlotinib	NA	Malignant cells	0.75409	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD8+ T cells	0.3408	1.19e-06
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD4+ T cells	0.279053	6.47e-19
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	0.261438	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	-0.293157	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	B cells	0.990586	1.74e-02
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-0.356605	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	-0.904545	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.852198	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-2.81041	1.43e-13
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD8+ T cells	0.32381	9.08e-07
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	0.412494	7.44e-11
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD8+ T cells	0.25349	2.35e-02
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.365357	0.00e+00
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.351878	1.36e-31
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.669429	0.00e+00
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.741609	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD8+ T cells	-0.336099	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	NK cells	-0.277523	3.45e-14
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	-0.354111	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	B cells	-0.363869	2.23e-07
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Erythrocytes	-0.36	4.40e-05
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	-0.615335	0.00e+00
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	1.04191	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	-0.795429	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	-1.78031	0.00e+00

Top

Expression of PTMA in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to PTMA

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating PTMA

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
PTMA	hsa-miR-1972	97.1905	NM_001099285
PTMA	hsa-miR-3926	96.5959	NM_001099285
PTMA	hsa-miR-545-3p	94.3469	NM_001099285
PTMA	hsa-miR-512-5p	94.3297	NM_001099285
PTMA	hsa-miR-651-3p	92.4979	NM_001099285
PTMA	hsa-miR-5571-5p	88.3143	NM_001099285
PTMA	hsa-miR-3658	84.5178	NM_001099285
PTMA	hsa-miR-3148	82.9449	NM_001099285
PTMA	hsa-miR-6885-3p	82.7342	NM_001099285
PTMA	hsa-miR-8054	82.0843	NM_001099285
PTMA	hsa-miR-548av-5p	82.0843	NM_001099285
PTMA	hsa-miR-548k	82.0843	NM_001099285

Page: 1

Top

Motifs and transcription factors (TFs) regulating PTMA

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
PTMA	taipale_tf_pairs__GCM1_ELF1_GTGCGGGCGGAAGTN_CAP_repr	ELF1; GCM1 (directAnnotation).
PTMA	metacluster_174.3	MBD2; NFYA; NFYB; NFYC; PBX3 (directAnnotation).
PTMA	metacluster_174.2	CEBPZ; CEBPZ; DRAP1; FOS; FOXI1; FOXI1; HMGXB3; IRF3; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYB; NFYB; NFYB; NFYB; NFYB; NFYC; NFYC; NFYC; NFYC; NFYC; NFYC; NFYC; PBX3; PBX3; SP2 (directAnnotation). NFYA; NFYA; NFYC; PBX1; PBX3 (inferredBy_Orthology).
PTMA	metacluster_191.2	ELK4; NR2C2; NR2C2; NR2C2; NR2C2 (directAnnotation). GABPA (inferredBy_Orthology).
PTMA	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	ETS2 (directAnnotation).
PTMA	metacluster_191.3	EHF; ELF1; ELF1; ELF1; ELF4; ELK1; ELK3; ELK3; ELK4; ELK4; ERF; ETS1; ETS2; ETV3; ETV4; ETV5; FEV; FEV; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; SPDEF; ZNF200 (directAnnotation). ELK1; ELK1; ELK3; ELK3; ELK4; ELK4; ETV1; ETV1; ETV4; ETV4; ETV4; ETV5; GABPA; GABPA (inferredBy_Orthology).
PTMA	taipale_cyt_meth__E2F2_GCGCGCGCGYW_eDBD_repr	E2F2 (directAnnotation).
PTMA	taipale_cyt_meth__ZNF385D_NCGTCGCGACGN_eDBD_meth	ZNF385D (directAnnotation).
PTMA	metacluster_197.2	E2F4; E2F7; E2F7; E2F7; E2F8; E2F8 (directAnnotation).
PTMA	taipale_tf_pairs__E2F1_ELK1_SGCGCNNNNNCGGAAGN_CAP_repr	E2F1; ELK1 (directAnnotation).
PTMA	taipale_tf_pairs__E2F1_HES7_RRCRCGYGYNNNNSGCGCSN_CAP_repr	E2F1; HES7 (directAnnotation).
PTMA	metacluster_166.4	BCLAF1; EHF; ELF1; ELF1; ELF1; ELF1; ELF1; ELF1; ELF2; ELF2; ELF4; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK3; ELK3; ELK3; ELK3; ELK4; ERG; ERG; ERG; ERG; ETS1; ETS1; ETS1; ETS1; ETS1; ETV1; ETV1; ETV1; ETV1; ETV2; ETV3; ETV4; ETV4; ETV4; ETV4; ETV4; ETV5; ETV7; FEV; FEV; FLI1; FLI1; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; GABPB1; GATAD1; PHF20; ZBTB25; ZBTB40 (directAnnotation). EHF; ELF1; ELF1; ELF3; ELF5; ELK3; ELK4; ERG; ETS1; ETV1; ETV2; ETV4; FLI1; GABPA; GABPA (inferredBy_Orthology).
PTMA	swissregulon__hs__ZBTB14	ZBTB14 (directAnnotation).
PTMA	metacluster_138.2	ELF1; ELF2; ELF4; ELK1; ELK1; ELK1; ELK1; ELK3; ELK4; ELK4; ELK4; ELK4; ELK4; ELK4; ELK4; ERF; ERG; ERG; ERG; ERG; ETS1; ETS1; ETS2; ETS2; ETV1; ETV1; ETV1; ETV2; ETV3; ETV4; ETV5; ETV5; FEV; FLI1; FLI1; GABPA; GABPA; KMT2B; SPDEF; SPDEF; SPDEF; ZBTB11; ZNF518A; ZNF580 (directAnnotation). ELF1; ELF2; ELF4; ELK1; ELK1; ELK3; ELK4; ERG; ETS1; ETS2; ETV1; ETV2; ETV3; ETV4; ETV5; FEV; FLI1; FLI1; GABPA; SPDEF; SPDEF (inferredBy_Orthology).
PTMA	metacluster_34.3	EGR1; ETS1; SETDB1; SIX5; SIX5; ZNF143; ZNF76 (directAnnotation).
PTMA	transfac_pro__M05894	ZNF565 (directAnnotation).
PTMA	metacluster_31.3	ZSCAN20; ZSCAN29 (directAnnotation).
PTMA	metacluster_22.36	BACH2 (directAnnotation).
PTMA	transfac_pro__M06005	ZNF232 (directAnnotation).
PTMA	transfac_pro__M06614	ZNF594 (directAnnotation).
PTMA	taipale_tf_pairs__ETV5_HOXA2_RSCGGWAATKR_CAP	ETV5; HOXA2 (directAnnotation).
PTMA	transfac_pro__M04748	GABPA (directAnnotation).
PTMA	metacluster_174.6	NFYA; NFYB; NFYB; NFYC (directAnnotation).
PTMA	transfac_public__M00024	E2F1 (directAnnotation).
PTMA	swissregulon__mm__E2f7	E2F7 (inferredBy_Orthology).
PTMA	taipale_tf_pairs__FOXO1_ELK3_RCCGGAWGTKKW_CAP	ELK3; FOXO1 (directAnnotation).
PTMA	taipale_tf_pairs__TEAD4_ETV1_RSCGGAAATRCM_CAP	ETV1; TEAD4 (directAnnotation).
PTMA	taipale_tf_pairs__ETV5_EVX1_RSCGGWAATKR_CAP	ETV5; EVX1 (directAnnotation).
PTMA	hdpi__FLI1	FLI1 (directAnnotation).
PTMA	jaspar__MA1708.1	ETV7 (directAnnotation).
PTMA	taipale_tf_pairs__TEAD4_ERG_RSCGGAAATRCC_CAP	ERG; TEAD4 (directAnnotation).
PTMA	cisbp__M02645	ETS1 (directAnnotation).
PTMA	taipale_tf_pairs__TEAD4_ERG_RSCGGAAATRCC_CAP_repr	ERG; TEAD4 (directAnnotation).
PTMA	taipale_tf_pairs__HOXB2_ETV4_ACCGGAAATGAN_CAP	ETV4; HOXB2 (directAnnotation).
PTMA	transfac_pro__M05560	AEBP2 (directAnnotation).
PTMA	transfac_pro__M06939	ZBTB11 (directAnnotation).
PTMA	transfac_pro__M02279	CREB1 (directAnnotation).
PTMA	metacluster_144.10	ZNF100 (directAnnotation).
PTMA	metacluster_97.2	GTF3A (inferredBy_Orthology).
PTMA	transfac_pro__M04923	ZBTB33 (directAnnotation).
PTMA	taipale_tf_pairs__TEAD4_ETV4_RCCGGAAATRCC_CAP	ETV4; TEAD4 (directAnnotation).
PTMA	kznf__GLI4_Schmitges2016_ChIP-seq	GLI4 (directAnnotation).
PTMA	transfac_pro__M05464	SALL1 (directAnnotation).
PTMA	metacluster_2.9	IRF2; IRF2; IRF2; PRDM1; PRDM1 (directAnnotation). PRDM1 (inferredBy_Orthology).
PTMA	transfac_pro__M06104	ZNF16 (directAnnotation).
PTMA	tfdimers__MD00079	E2F1; FOXM1 (directAnnotation).
PTMA	transfac_pro__M05647	ZNF875 (directAnnotation).
PTMA	metacluster_141.2	E2F2; E2F3 (directAnnotation).
PTMA	transfac_pro__M06781	ZNF107 (directAnnotation).
PTMA	metacluster_140.5	NR2E1 (directAnnotation). NR2E1; NR2E1; NR2E1 (inferredBy_Orthology).

Page: 1 2 3 4 5 6

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."